Thursday, 5 March 2020
Department of Health
Medicinal Products Availability
885. To ask the Minister for Health if provision has been made by the HSE to expand the availability of anti-IL-5 therapies for severe asthma in 2020; the number of patients that were able to access same in 2019; the number expected to be able to access same in 2020; and if he will make a statement on the matter. [3806/20]
Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for the administration of the community drug schemes; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.